List of Excipients in Branded Drug DEXLANSOPRAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TWI PHARMACEUTICALS INC	DEXLANSOPRAZOLE	dexlansoprazole	24979-703	ALUMINUM OXIDE
TWI PHARMACEUTICALS INC	DEXLANSOPRAZOLE	dexlansoprazole	24979-703	CARRAGEENAN
TWI PHARMACEUTICALS INC	DEXLANSOPRAZOLE	dexlansoprazole	24979-703	FD&C BLUE NO. 2
TWI PHARMACEUTICALS INC	DEXLANSOPRAZOLE	dexlansoprazole	24979-703	FERRIC OXIDE RED

Generic Drugs Containing DEXLANSOPRAZOLE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	dexlansoprazole	0378-2085	CARRAGEENAN
Mylan Pharmaceuticals Inc	dexlansoprazole	0378-2085	ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B
Mylan Pharmaceuticals Inc	dexlansoprazole	0378-2085	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	dexlansoprazole	0378-2085	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in DEXLANSOPRAZOLE?

# Of NDCs	Excipient
1	ACID YELLOW 23
5	AMMONIA
1	BLUE 1
5	BUTYL ALCOHOL

Dexlansoprazole Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Dexlansoprazole is a small-molecule proton-pump inhibitor whose commercial differentiation depends on its dual delayed-release delivery system rather than its active ingredient alone. The formulation uses two populations of enteric-coated granules that release dexlansoprazole at different points in the gastrointestinal tract. This design supports twice-daily acid suppression from a once-daily capsule and creates formulation, manufacturing, and intellectual-property barriers for generic developers.

The strongest opportunities are in lower-cost multiparticulate manufacturing, sprinkle and liquid dosage forms, pediatric delivery, dysphagia products, and differentiated products using the dexlansoprazole racemate or alternative release profiles. Biosimilar risk is not relevant because dexlansoprazole is a chemically synthesized small molecule.

What is dexlansoprazole and how is it formulated?

Dexlansoprazole is the R-enantiomer of lansoprazole. Takeda markets it in the United States as Dexilant delayed-release capsules in 30 mg and 60 mg strengths. The FDA approved Dexilant in 2009 for healing and maintenance of erosive esophagitis and for treatment of heartburn associated with gastroesophageal reflux disease. The 30 mg strength also has an indication for symptomatic nonerosive GERD in adults.[1]

The product uses a dual delayed-release mechanism:

Formulation element	Function
First granule population	Releases dexlansoprazole at an earlier intestinal pH
Second granule population	Releases dexlansoprazole at a higher intestinal pH
Enteric polymer coating	Protects the acid-labile drug from gastric degradation
Sugar spheres	Provides multiparticulate carrier cores
Magnesium carbonate	Supports drug-layer stability and microenvironmental pH control
Hypromellose	Binds and protects the drug layer
Methacrylic acid copolymer	Provides pH-dependent enteric release
Polyethylene glycol	Plasticizer and coating-process aid
Talc and titanium dioxide	Coating processing and opacity
Polysorbate 80	Wetting and dispersion aid
Gelatin capsule shell	Delivers the granule blend in an oral capsule

The FDA label identifies sugar spheres, magnesium carbonate, sucrose, hypromellose, methacrylic acid copolymer, polyethylene glycol, talc, titanium dioxide, polysorbate 80, capsule colorants, and gelatin among the product’s inactive ingredients.[1]

Why does the dual delayed-release system matter commercially?

The formulation provides the main commercial distinction between dexlansoprazole and conventional proton-pump inhibitors. Standard delayed-release PPIs generally release one dose after gastric emptying. Dexilant releases one portion earlier and another portion later, extending pharmacodynamic exposure.

Patients can take Dexilant without regard to meals, according to the FDA label. That property gives the product a positioning advantage in adherence-sensitive GERD markets, although generic lansoprazole, omeprazole, pantoprazole, and esomeprazole remain lower-cost alternatives.[1]

The commercial value of the formulation rests on four factors:

1. Multiparticulate granules provide flexible release engineering.
2. Enteric protection is necessary because dexlansoprazole is acid-labile.
3. The two release populations require tight control of coating thickness and dissolution.
4. The capsule can be opened and the granules administered with soft food, subject to label conditions.

These attributes create development opportunities but also raise manufacturing costs and regulatory complexity.

What excipients are most important in dexlansoprazole development?

Enteric polymers

Methacrylic acid copolymers are central to the release strategy. Different polymer grades can produce distinct dissolution thresholds, allowing developers to establish two release pulses. Selection affects:

• pH threshold;
• lag time;
• coating weight gain;
• mechanical strength;
• storage stability;
• alcohol sensitivity;
• dissolution reproducibility.

A generic developer cannot treat the product as a simple enteric-coated capsule. It must reproduce a clinically relevant dual-release profile or demonstrate that its alternative profile delivers equivalent performance under the applicable FDA pathway.

Alternative polymers, including cellulose acetate phthalate, hypromellose phthalate, and polyvinyl acetate phthalate, may provide formulation freedom. Their use would require careful evaluation of dissolution, residual solvents, coating defects, and process scale-up.

Alkaline stabilizers

Magnesium carbonate is commercially important because it can create a less acidic microenvironment around the benzimidazole drug. Other alkaline materials, such as magnesium oxide, calcium carbonate, sodium bicarbonate, or tromethamine, could support alternative formulations.

The substitution risk is material. Alkaline excipients can change:

• chemical degradation rates;
• drug-layer uniformity;
• granule hardness;
• coating adhesion;
• capsule-fill density;
• dissolution after accelerated storage.

A replacement excipient that improves stability but changes intestinal release may create bioequivalence problems.

Drug-layer binders

Hypromellose supports adhesion between dexlansoprazole and the sugar-sphere substrate. Binder concentration affects granule strength and coating performance. Excess binder can slow hydration and alter release. Insufficient binder can increase attrition, create fines, and produce dose-uniformity failures.

Low-substituted hydroxypropyl cellulose, povidone, or other binders could support alternative processes, but each would require evaluation for drug-excipient compatibility and granule friability.

Plasticizers and surfactants

Polyethylene glycol improves flexibility in the enteric coating. Polysorbate 80 improves wetting and coating dispersion. Both materials can influence long-term stability.

Commercial development should assess:

• plasticizer migration;
• coating tack;
• moisture uptake;
• peroxide-related degradation;
• interaction with the drug layer;
• dissolution after storage.

Excipient suppliers with low-peroxide, pharmaceutical-grade polyethylene glycol and tightly controlled polysorbate 80 impurity profiles may have a selling point in PPI formulations.

What formulation opportunities exist for dexlansoprazole?

Generic dual-release capsules

The most direct opportunity is an AB-rated generic capsule using two enteric-coated granule populations. The product must address:

• two distinct release pulses;
• particle-size distribution;
• coating weight gain;
• drug loading;
• capsule-fill uniformity;
• dissolution across multiple pH stages;
• stability under humidity stress;
• granule segregation during transport.

The principal commercial advantage is access to an established prescription market. The principal disadvantage is higher manufacturing cost compared with single-pulse generic PPIs.

Sprinkle and dysphagia products

Dexilant capsules may be opened and administered with certain soft foods under the prescribing information. A developer could pursue a product optimized for:

• patients with dysphagia;
• older adults;
• feeding-tube administration;
• pediatric patients who cannot swallow capsules;
• hospital and long-term-care settings.

The opportunity is strongest if the product has validated granule integrity after administration through a feeding tube. Tube compatibility, clogging risk, dose recovery, and storage after dispersion would become important product attributes.

Oral suspension or sachet

A ready-to-use suspension could improve administration for pediatric and institutional patients. The main technical problems would be maintaining the two granule populations without premature release and preventing sedimentation or aggregation.

A dry suspension or sachet containing coated granules may be more practical than an aqueous product. It would reduce chemical stability risk while preserving multiparticulate delivery.

Orally disintegrating tablet

An orally disintegrating tablet could improve convenience, but compression creates a major risk of damaging enteric coatings. A viable design would likely require protected mini-tablets or coated pellets embedded in a rapidly disintegrating matrix.

This approach could support a 505(b)(2) strategy if the product has a clinically meaningful administration advantage and does not merely duplicate the capsule.

Alternative release profiles

A once-daily product with an optimized first and second pulse could target patients with nocturnal symptoms or incomplete control on standard PPIs. A higher-strength or modified-release product could also target difficult-to-control GERD, subject to clinical and regulatory requirements.

The commercial case would need to demonstrate value beyond generic PPI substitution. Formulation complexity alone is unlikely to sustain premium pricing after generic entry.

How does dexlansoprazole compare with competing acid-suppression drugs?

Product	Active ingredient	Release strategy	Competitive position
Dexilant	Dexlansoprazole	Dual delayed release	Differentiated dosing and multiparticulate delivery
Prevacid	Lansoprazole	Delayed release	Established generic competition
Nexium	Esomeprazole	Delayed release	Strong brand recognition and generic availability
Protonix	Pantoprazole	Delayed release	Broad generic and hospital use
Prilosec	Omeprazole	Delayed release	Low-cost, high-volume generic
Voquezna	Vonoprazan	Potassium-competitive acid blocker	Newer mechanism and competing acid-control profile

Dexlansoprazole competes against lower-cost PPIs and against vonoprazan-based products. Its strongest differentiation is administration flexibility and dual-pulse exposure. Its weakest commercial position is the availability of inexpensive once-daily alternatives.

When does dexlansoprazole lose exclusivity?

Dexlansoprazole’s regulatory exclusivity is distinct from its patent protection. The initial new-drug exclusivity period associated with the 2009 U.S. approval has expired. Market access now depends primarily on patent status, FDA generic approvals, litigation, and settlement terms.

The relevant exclusivity framework is:

Protection category	Dexlansoprazole status
New chemical entity exclusivity	Historical period expired
Pediatric exclusivity	Must be assessed from FDA records for the specific product
Orphan exclusivity	Not the primary basis of Dexilant protection
Patent protection	Historically focused on the active enantiomer, formulations, and release systems
Biosimilar exclusivity	Not applicable
Generic competition	Governed through ANDA and Paragraph IV processes

The Orange Book remains the controlling source for current listed patents, expiration dates, and FDA-recognized patent certifications.[2] Patent analysis should separate patents covering dexlansoprazole itself from patents covering multiparticulate formulations, enteric coatings, dosing methods, and manufacturing processes.

What patents protect dexlansoprazole products?

The principal patent categories are:

Active-ingredient and enantiomer patents

Early patent claims focused on the optically active benzimidazole compound and its pharmaceutical use. These patents generally have earlier expiration dates than later formulation patents.

Dual delayed-release formulation patents

These claims can cover:

• two populations of coated granules;
• different enteric release thresholds;
• specific polymer combinations;
• pH-dependent dissolution profiles;
• drug-layer composition;
• capsule dosage forms.

These patents are commercially more relevant to generic developers because a simple substitution of excipients may still infringe a claim directed to the release architecture.

Method-of-use patents

Potential method claims may address treatment of GERD, erosive esophagitis, maintenance therapy, or administration without regard to meals. Method-of-use patents can create labeling and skinny-label issues for ANDA applicants.

Manufacturing patents

Process claims may cover:

• fluid-bed coating;
• granule layering;
• sequential enteric coating;
• drying conditions;
• particle-size control;
• blending of the two granule populations.

Process patents are harder to detect through finished-product testing but can affect contract manufacturing and supply-chain diligence.

Which companies are challenging dexlansoprazole exclusivity?

Generic manufacturers typically challenge small-molecule PPI patents through ANDAs with Paragraph IV certifications. The commercial risk is determined by:

• the number of approved ANDAs;
• the number of tentative approvals;
• patent litigation outcomes;
• 30-month stays;
• settlement dates;
• authorized-generic arrangements;
• the scope of remaining formulation claims.

Dexlansoprazole does not face biosimilar competition. Any competitive threat comes from conventional generics, dexlansoprazole generics, 505(b)(2) products, and alternative acid-suppression medicines.

A current company-by-company challenge list requires the latest FDA Orange Book, FDA approval records, and federal court dockets. Historical patent records alone do not establish current launch timing.

What is the litigation and settlement risk?

For a formulation-heavy product, litigation risk is usually concentrated in three areas:

1. Whether the generic’s two release populations infringe formulation claims.
2. Whether the applicant can establish bioequivalence despite different excipients.
3. Whether method-of-use claims restrict the proposed label.

A Paragraph IV filing can trigger Hatch-Waxman litigation and a potential 30-month stay of approval under the statutory framework. Settlement agreements may provide a negotiated entry date, an authorized generic arrangement, or restrictions on certain indications.

The commercial impact depends less on the number of patents than on whether a remaining claim covers the core dual-release architecture. A narrow coating-process patent may be designed around. A broad claim covering two pH-triggered release populations is more commercially significant.

How strong is the dexlansoprazole patent estate?

The estate is strongest when claims cover the complete combination of:

• dexlansoprazole;
• two separate granule populations;
• different enteric release thresholds;
• defined coating compositions;
• pharmaceutical dosage forms.

The estate is weaker where claims depend on easily substituted excipients or narrow process conditions. Generic developers can seek design-around options by changing:

• enteric polymer chemistry;
• alkaline stabilizer;
• binder;
• granule core;
• coating sequence;
• capsule versus sachet presentation;
• release-pulse timing.

A strong freedom-to-operate analysis must review issued claims, prosecution history, terminal disclaimers, patent-family relationships, and Orange Book listing status. Formulation similarity is not the same as infringement, and an apparently different excipient system may still fall within a functional or structural claim.

What commercial opportunities exist for excipient suppliers and manufacturers?

Excipient suppliers

The most attractive supply opportunities involve:

• low-peroxide polyethylene glycol;
• pharmaceutical-grade methacrylic acid copolymers;
• controlled-particle-size magnesium carbonate;
• low-moisture sugar spheres;
• high-purity hypromellose;
• coating systems optimized for multiparticulates;
• ready-to-use aqueous or organic enteric dispersions.

Suppliers can differentiate through technical support, regulatory documentation, and batch-to-batch dissolution consistency.

Contract manufacturers

CMOs with fluid-bed coating and multiparticulate expertise have a stronger position than conventional capsule fillers. Required capabilities include:

• drug layering onto inert cores;
• controlled coating weight gain;
• segregation-resistant blending;
• in-process particle-size analysis;
• staged dissolution testing;
• low-humidity handling;
• scale-up from laboratory to commercial fluid-bed equipment.

The main manufacturing barrier is process reproducibility. Small changes in spray rate, inlet temperature, atomization pressure, or drying endpoint can shift the release profile.

Product developers

Commercially attractive development paths include:

Product concept	Strategic rationale	Main barrier
AB-rated dual-release capsule	Direct generic substitution	Bioequivalence and patent risk
Sprinkle granules	Dysphagia and pediatric use	Administration and stability validation
Dry suspension	Institutional and pediatric delivery	Maintaining dual-pulse release
Orally disintegrating tablet	Convenience differentiation	Coating damage during compression
505(b)(2) modified-release product	Potential lifecycle extension	Clinical and patent requirements
Lower-cost regional product	Access in price-sensitive markets	CMC scale and regulatory variation

What generic launch scenarios exist?

Early negotiated entry

A settlement may allow launch before the latest asserted patent expiration. This scenario produces rapid price erosion, particularly if several manufacturers enter simultaneously.

Single generic launch

A single approved generic may initially preserve some price premium. The market can remain commercially viable if the product requires specialized multiparticulate manufacturing.

Multi-generic entry

Multiple ANDA approvals usually lead to substantial price compression. The brand may retain revenue through contracts, authorized generic supply, or payer positioning, but the dual-release technology alone is unlikely to prevent substitution.

505(b)(2) differentiated entry

A company could seek approval for a new dosage form, administration method, or patient population. This strategy may support a separate commercial position but carries greater development cost than an ANDA.

What is the FDA regulatory status of dexlansoprazole?

Dexilant is an FDA-approved prescription product. The regulatory framework for follow-on products depends on the proposed pathway:

• ANDA for a therapeutically equivalent generic;
• 505(b)(2) NDA for a modified formulation or delivery system;
• full NDA for a materially new clinical product.

FDA review will focus on pharmaceutical equivalence, bioequivalence, dissolution, stability, impurities, and manufacturing controls. For multiparticulate products, dissolution testing must distinguish the two release events rather than relying only on a single cumulative endpoint.[1,3]

Key Takeaways

• Dexlansoprazole’s principal value is its dual delayed-release multiparticulate formulation.
• The most important excipients are the enteric polymer, alkaline stabilizer, binder, plasticizer, surfactant, and inert core.
• Generic development is technically more difficult than development of a conventional single-pulse PPI.
• The strongest commercial opportunities are generic dual-release capsules, sprinkle products, dry suspensions, and dysphagia-focused presentations.
• Biosimilar risk does not apply because dexlansoprazole is a small molecule.
• Patent risk is concentrated in formulation architecture, method-of-use claims, and manufacturing processes.
• Generic entry can produce rapid price erosion once multiple ANDAs are approved.
• Excipient suppliers and CMOs with validated multiparticulate coating capabilities have the clearest enabling opportunities.

FAQs

Can dexlansoprazole be formulated without methacrylic acid copolymer?

Yes. Alternative enteric polymers may be technically feasible, but the developer must reproduce acid protection, release thresholds, stability, and bioequivalent performance.

Is dexlansoprazole suitable for a pediatric liquid formulation?

Potentially. A dry suspension or granule-based product is more practical than a conventional aqueous solution because the active ingredient requires protection from gastric acid and moisture-related degradation.

What is the main excipient risk in a dexlansoprazole generic?

The main risk is changing an excipient in a way that shifts one of the two release pulses. A chemically acceptable substitute may still produce a clinically or regulatorily unacceptable dissolution profile.

Can an orally disintegrating tablet replace the Dexilant capsule?

It may be possible, but compression can damage enteric coatings. The formulation would likely require protected mini-tablets or coated pellets embedded in a rapidly disintegrating matrix.

Does vonoprazan eliminate the commercial opportunity for dexlansoprazole?

No. Vonoprazan adds competitive pressure, but dexlansoprazole retains opportunities in generic substitution, meal-independent dosing, multiparticulate delivery, and patient segments that value flexible administration.

References

1. U.S. Food and Drug Administration. (2023). Dexilant (dexlansoprazole) delayed-release capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2009). FDA approves Kapidex delayed-release capsules for gastroesophageal reflux disease.
4. U.S. Food and Drug Administration. (2019). ANDAs for certain highly variable drugs: Guidance for industry.